Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20577746 | 0.88 | KCNK3 (0.59) | KMT2AMEN1KCNK3RAB9ANPC1 | |
| SCHEMBL20577976 | 0.88 | KCNK3 (0.60) | KMT2AMEN1KCNK3RAB9ANPC1 | |
| SCHEMBL20577964 | 0.87 | RAB9A (0.50) | KMT2AMEN1KCNK3RAB9ANPC1 | |
| SCHEMBL20577988 | 0.84 | RAB9A (0.56) | KMT2AMEN1RAB9ANPC1MAPK14 | |
| SCHEMBL20577724 | 0.82 | SERPINE1 (0.51) | KMT2AMEN1RAB9ANPC1MAPK14 | |
| SCHEMBL20577784 | 0.82 | HDAC1 (0.52) | KMT2AMEN1RAB9ANPC1MAPK14 | |
| SCHEMBL29448796 | 0.81 | KMT2A (0.54) | KMT2AMEN1KCNK3RAB9ANPC1 | |
| SCHEMBL17664369 | 0.80 | MAPT (0.61) | KMT2AMEN1KCNK3RAB9AHTT | |
| SCHEMBL21407896 | 0.78 | KCNQ3 (0.56) | KMT2AMEN1RAB9ANPC1MAPK14 | |
| SCHEMBL28660926 | 0.77 | KCNQ3 (0.49) | KMT2AMEN1RAB9ANPC1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | KMT2A 3193/4885MEN1 1284/4885KCNK3 2096/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | KMT2A 3193/4885MEN1 1284/4885KCNK3 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.